Recombinant Mouse FCGRT & B2M Heterodimer Protein (Active)
| Code | Size | Price |
|---|
| PKSM040322-100ug | 100ug | £832.00 |
Quantity:
| PKSM040322-1mg | 1mg | £4,795.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Further Information
Abbreviation:
FCGRT & B2M Heterodimer
Accession:
P55899&P01887
Activity:
Measured by its ability to bind human IgG1 in functional ELISA.
Background:
β-2-Microglobulin (B2M) is a secreted protein with 1 Ig-like C1-type (immunoglobulin-like) domain which belongs to the beta-2-microglobulin family. B2M component of major histocompatibility complex (MHC) class I molecules, involved in the presentation of peptide antigens to the immune system. Polymers of beta 2-microglobulin can be found in tissues from patients on long-term hemodialysis. B2M is a protein found on the surface of many cells and plentiful on the surface of white blood cells. Serum B2M concentration is increased in renal diseases, various malignant diseases and some inflammatory and autoimmune disorders. B2M may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. B2M has been shown as a marker for monitoring inflammatory disease activity and it appears likely to have a destructive role in amyloidosis-related arthritis. B2M might be involved in the OA (osteoarthritis) pathogenesis. Defects in B2M are the cause of hypercatabolic hypoproteinemia. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation. B2M could be a potential therapeutic target in ovarian cancer.
Calculated MW:
43.5 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
35 & 12 kDa
Purity:
> 95 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Ser 297&Met 1-Met 119(105Ala/Asp)
Target Synonym:
FcRn
UNIProt ID:
P55899&P01887